- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 ; volume:7 ; number:1 ; day:1 ; month:8 ; year:2019 ; pages:1-6 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (1.8.2019), 1-6, 12.2019
- Creator
-
Lemal, Richard
Tournilhac, Olivier
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0686-x
- URN
-
urn:nbn:de:101:1-2019122602363744914683
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lemal, Richard
- Tournilhac, Olivier
- SpringerLink (Online service)
Other Objects (12)
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Evolving strategies for addressing CAR T-cell toxicities
CAR T-Cell therapy
Optimal CAR T-cell immunotherapy strategies for a leukemia treatment model
Recent advances in CAR T-cell therapy for lymphoma in China
CAR T-Cell therapy for the management of mantle cell lymphoma
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
The CAR T‐Cell Mechanoimmunology at a Glance
CAR T-cell therapy and critical care : A survival guide for medical emergency teams